MINNEAPOLIS, MINNESOTA – gener8tor announced the launch of the Midwest COVID-19 Innovation Showcase through the gBETA Medtech program at the end of May, receiving a total of 113 applications to pitch at the showcase. After careful review, the selection committee has selected 14 teams to pitch at the Midwest COVID-19 Innovations Showcase. The Midwest COVID-19 Innovation Showcase will take place on July 16, 2020, from 12:00 PM – 4:00 PM CT.
The 14 accepted teams will each get personalized coaching to refine their pitch and help determine what they need to succeed, pitch their idea virtually in front of a large audience and meet with healthcare stakeholders in small mentoring sessions to receive feedback, advice and resources that can help advance the implementation of their innovations.
Registration is now open to anyone that wants to hear how these 14 teams are helping us fight the current pandemic. gbetamedtech.com/innovation-showcase.
The Virtual Pitch Session consists of 4 min pitches + 2 min Q&A. You will hear about innovative ideas that are tackling COVID-19’s toughest challenges within therapeutics, diagnostics, remote patient monitoring and personal protective equipment.
Private Virtual Mentoring Sessions will take place after the Pitch Session. These are pre-scheduled curated 15 min mentoring sessions between presenting teams and selected healthcare stakeholders. Only a handful of event attendees will be selected to participate.
The Midwest COVID-19 Innovation Showcase is organized by gener8tor in partnership with University Enterprise Labs, the Biomedical Advanced Research and Development Authority, Boston Scientific, Purdue Discovery to Innovation Accelerator, Purdue Foundry, Mayo Clinic, University of Minnesota, Medical Alley Association, and University of Missouri. For more information visit gbetamedtech.com/innovation-showcase.
NOTA’s single-use, time-release chemical packet is placed into a face mask and activated by the user’s breath to produce on-demand nitric oxide (NO). This is the first self-administered treatment and/or prophylaxis for a wide range of viral respiratory infections, including COVID-19.
Liberate Medical’s VentFree Respiratory Muscle Stimulator is a non-invasive neuromuscular electrical stimulator designed to reduce abdominal muscle atrophy and reduce the amount of time adult patients spend on mechanical ventilation. In doing so, Liberate Medical can considerably improve patient outcomes, reduce strain on critical care resources and save provider cost.
Celista Pharmaceuticals’ nasal spray is an immunotherapy agent for COVID-19 that can be used prophylactically to protect amongst others, care home residents and front-line health workers.